Kuvan - 2007 FDA approvals

Drug: Kuvan (sapropterin dihydrochloride)
Indication: Phenylketonuria
Company: BioMarin
Approval Date: December 18, 2007

Scoop: Phenylketonuria (PKU) is a rare genetic disorder that causes mental retardation, smaller brain size, delayed speech and other neurological problems. This disease is a result of the enzyme phenylalanine hydroxylase (PAH) not functioning properly in the body. Kuvan works by increasing PAH enzyme activity in PKU patients with some residual PAH enzyme function. This then leads to an increased breakdown (metabolism) of phenylalanine (Phe), resulting in lower levels of Phe in the blood.

Kuvan - 2007 FDA approvals

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.